Moving forward, Vivani will focus on developing NPM-115, NPM-139 and its emerging pipeline of innovative miniature, ultra long-acting drug implants to treat patients with chronic diseases and high unmet medical need. The recent preclinical demonstration of NPM-139 comes on the heels of having rapidly enrolled and successfully administered the initial implants in LIBERATE-1, a first-in-human study with NPM-115, which is expected to pave the road for NPM-139 as development continues for both programs. Today, the Biopharm Division has grown to 35 full-time employees and its headquarters and operations are located at 1350 S. Loop Road, Alameda, California 94502.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VANI:
- Vivani Medical reports Q4 EPS (11c) vs. (12c) last year
- Vivani Medical prices 7.4M shares at $1.12 in private placement financing
- H.C. Wainwright bullish on Vivani following positive semaglutide implant data
- Vivani Medical’s Innovative Implants and Promising Trials Justify Buy Rating
- Vivani Medical announces preclinical weight loss data for NPM-139